Pharmafile Logo

patient expectations

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Lilly reports positive data from its phase 3 ulcerative colitis trial

IL-23 blocker mirikizumab helped patients achieve clinical remission in 12-week induction study

- PMLiVE

Healthcare PR agency Spink merges with emotive

Spink’s PR and public affairs expertise will become a part of emotive’s medical and brand offering

Accession Logo

Accession announces investment to support next phase of growth

March 2021: Accession Healthcare Consulting (Accession), a specialist pharma market access consultancy, today announces that it has received private investment from a group of highly experienced healthcare and technology investors...

Accession

- PMLiVE

EU considers blocking COVID-19 vaccine exports to the UK

EC president Ursula von der Leyen says she wants "to see reciprocity and proportionality in exports"

- PMLiVE

Merck & Co signs deal with Amathus for neurodegenerative diseases

Collaboration will focus on developing small molecules for undisclosed disease targets

- PMLiVE

UK COVID-19 vaccination drive hit with supply delays over the coming weeks

Weekly vaccine supplies face a 'significant reduction' from 29 March

- PMLiVE

A new era for UK-Japanese scientific research relations

Japan’s biopharmaceutical firms contributed $62.4bn, or 1.3% of GDP, to the country’s economic output in 2019

Out Of Office: The New Normal for Ad Agencies

Covid has made working from home mandatory for most agencies. Life after lockdown may never be the same.

Life Healthcare Communications

- PMLiVE

GSK and Medicago initiate late-stage COVID-19 vaccine study

Plant-based, adjuvanted vaccine candidate received FDA fast track designation in February

- PMLiVE

Create Health announces relaunch under new creativity banner

Healthcare agency announces relaunch 12 months after management buy-out

- PMLiVE

EU announces ‘top-up’ of ten million Pfizer/BioNTech vaccines in Q2

Brings total number of doses of the vaccine to be delivered in Q2 to over 200 million

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links